Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The strong growth outlook comes from Global leading the way in the fight against CoViD19, by offering 15 Minute Rapid IgG/IgM Tests for Venous Blood, & Fingertip Blood (POC), and 50 Minute rt-PCR Tests for CoViD19 with All the Tests Being FDA EUA Authorized, one of the largest lines of tests for CoViD19 SARS2, is prepared to help in the fight against CoViD19 SARS2.
Global WholeHealth Partners recognizes that there is a crucial need for faster testing and faster results when it comes to fighting the COVID. Global WholeHealth Partners knows that the quicker the test results can be reviewed by a Front-Line Healthcare Worker, the quicker we can stop the spread of this disease.
Global WholeHealth Partners now has the means to identify and test for Alzheimer's disease using a Micro-Well Reader or Lateral Flow Test to measure the certain brain enzymes during the data collection process used in a positive diagnosis. This was disclosed in an 8K filed March 21, 2021 which can be found by clicking here.
"This could simply be described as nothing short of a Medical Breakthrough in Alzheimer's Disease Diagnostic Testing for us," said Charles Strongo, CEO of Global WholeHealth Partners Corp. (OTC:GWHP).
Hell yea brother! $GWHP
You love to see it $GWHP
Lets goooooooo all I see is green $$$$
Game on ! $GWHP
FDA authorization #SHH
Awesome DD Mr Bar !!
“Hopefully AstraZeneca can get their application into the Food and Drug Administration as soon as possible so that we may see FDA authorization of the vaccine within the next 4 to 6 weeks,” Strongo expressed as he referred to an article from the Associated Press found here.
“We (Global) have been early supporters of the AstraZeneca vaccine and we’ve already secured the global distribution rights to sell this vaccine anywhere in the world,” Mr. Strongo affirmed.
"This could simply be described as nothing short of a Medical Breakthrough in Alzheimer's Disease Diagnostic Testing for us," said Charles Strongo, CEO of Global WholeHealth Partners Corp. (OTC:GWHP).
Global WholeHealth Partners now has the means to identify and test for Alzheimer's disease using a Micro-Well Reader or Lateral Flow Test to measure the certain brain enzymes during the data collection process used in a positive diagnosis. This was disclosed in an 8K filed March 21, 2021 which can be found by clicking here.
“We believe this announcement couldn’t come at a better time for us as we are partnering with Nunzia Pharmaceutical and their products for Neurological disorders,” said Mr. Strongo
Mr. Charles Strongo, the Chairman and CEO of Global WholeHealth Partners Corp, said, "The Company's goal is to offer the fastest and most reliable in-vitro diagnostic tests on the market, while keeping ahead in R&D, by offering FDA Approved Troponin I Whole Blood, Influenza A & B, and Strep A. The Company also has international testing, which is not sold in the USA, with an FDA Certificate of Exportability (2260-11-2019) for tests like ZIKA, Rapid Ebola, Rapid Dengue Fever Antibody, and Antigen, Rapid Tuberculosis (TB), Rapid Malaria, and many other rapid tests."
“Early detection for Dementia disease is not only crucial for patients and their quality of life, but this data is also used by researchers to seek out commonalities, causes and hopefully cures,” commented Strongo.
“Nunzia Pharmaceutical with nutraceutical for anxiety and stress based on their patented formula and their pharmaceutical drug they are planning on bringing through the FDA, which specifically works on the Hippocampus part of the brain, dealing with stress, memory, and fine motor skills are a perfect fit for Global’s diagnostic tests,” says Mr. Strongo. Nutritional deficiencies
“We believe this announcement couldn’t come at a better time for us as we are partnering with Nunzia Pharmaceutical and their products for Neurological disorders,” said Mr. Strongo.
“Nunzia Pharmaceutical with a nutraceutical for anxiety and stress based on their patented formulas and there pharmaceutical drug there are planning on bringing through the FDA, which specifically works on the Hippocampus part of the brain, dealing with stress, memory, and fine motor skills are a perfect fit for Global’s diagnostic tests.”
“We believe this announcement couldn’t come at a better time for us as we are partnering with Nunzia Pharmaceutical and their products for Neurological disorders,”
Mr. Charles Strongo, the Chairman and CEO of Global WholeHealth Partners Corp, said, "The Company's goal is to offer the fastest and most reliable in-vitro diagnostic tests on the market, while keeping ahead in R&D, by offering FDA Approved Troponin I Whole Blood, Influenza A & B, and Strep A. The Company also has international testing, which is not sold in the USA, with an FDA Certificate of Exportability (2260-11-2019) for tests like ZIKA, Rapid Ebola, Rapid Dengue Fever Antibody, and Antigen, Rapid Tuberculosis (TB), Rapid Malaria, and many other rapid tests."
“Early detection for ASD disease is not only crucial for patients and their quality of life, but this data is also used by researchers to seek out commonalities, causes and hopefully cures,” commented Strongo.
“We believe this announcement couldn’t come at a better time for us as we are working with Nunzia Pharmaceutical and their future treatment for ASD,” said Mr. Strongo.
Looking for an update to send us moving
great DD here $GWHP moving forward quickly
yoyo Mr W how are you
Good Morning GWHP
“There is no better way to Stop the Spread of COVID-19 and its various mutated strains then by utilizing the rapid antibody test kits that we offer to accurately detect those who have become infected and having them immediately quarantine,” says Charles Strongo, CEO of Global WholeHealth Partners, Corp
“We (Global) have been early supporters of the AstraZeneca vaccine and we’ve already secured the global distribution rights to sell this vaccine anywhere in the world,” Mr. Strongo affirmed
Mr. Charles Strongo, the Chairman and CEO of Global WholeHealth Partners Corp., said, "The Company's goal is to offer the fastest and most reliable in-vitro diagnostic tests on the market, while keeping ahead in R&D, by offering FDA Approved Troponin I Whole Blood, Influenza A & B, and Strep A. The Company also has international testing, which is not sold in the USA, with an FDA Certificate of Exportability (2260-11-2019) for tests like ZIKA, Rapid Ebola, Rapid Dengue Fever Antibody, and Antigen, Rapid Tuberculosis (TB), Rapid Malaria, and many other rapid tests."
The marketing and sales partnership Nunzia Pharmaceutical with 8k filing dated 04/19/2021, gives Global the ability to sell the AstraZeneca Vaccine and the Johnson & Johnson vaccine and other products of Nunzia including their patented nutraceutical for stress and anxiety and soon FDA approved drug for ASD (Autistic Spectrum of Disorders), including Autism, ADD, ADHD, Fragile X, and PTSD. The Nunzia Nutraceutical aids in Nutritional deficiencies and therefore helps people
“Early detection for Dementia disease is not only crucial for patients and their quality of life, but this data is also used by researchers to seek out commonalities, causes and hopefully cures,” commented Strongo.
“We believe this announcement couldn’t come at a better time for us as we are partnering with Nunzia Pharmaceutical and their products for Neurological disorders,” said Mr. Strongo. “Nunzia Pharmaceutical with nutraceutical for anxiety and stress based on their patented formula and their pharmaceutical drug they are planning on bringing through the FDA, which specifically works on the Hippocampus part of the brain, dealing with stress, memory, and fine motor skills are a perfect fit for Global’s diagnostic tests,” says Mr. Strongo.
San Clemente, CA, April 20, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Global WholeHealth Partners (OTC:GWHP) now has the means to identify and test for Dementia using a Micro-Well Reader or Lateral Flow Test to measure the certain brain enzymes during the data collection process used in a positive diagnosis. This was disclosed in an 8K filed March 21, 2021 which can be found by clicking here. "This could simply be described as nothing short of a Medical Breakthrough in Dementia Diagnostic Testing.” -- said Charles Strongo, CEO of Global WholeHealth Partners, Corp (OTC:GWHP).
Yessir! $GWHP $1 land here we come
Yessir! $GWHP $1 land here we come
"It is phenomenal that people are signing up for Health Karma and getting the help they need. With two weeks remaining in the campaign, we hope that others will take advantage of this opportunity. We are seeing business growth because the bottom line is people are in need of convenient health care solutions that are easy-to-use and affordable. There is no better reward than to build a business that is able to give back to the community while simultaneously continuing to build shareholder value," stated Michael Swartz, President of Health Karma.
ready for more tomorrow $GWHP
agreed, $GWHP showing its colors here
agreed, RSI looking nice, time to scoop $GWHP
Nice volume holding .50 as support $GWHP
you love to see it $GWHP
yessir! $GWHP rare low. Scoop what you can imo
insane lows here $GWHP $1 time to LOAD UP
The marketing and sales partnership Nunzia Pharmaceutical with 8k filing dated 04/19/2021, gives Global the ability to sell the AstraZeneca Vaccine and the Johnson & Johnson vaccine and other products of Nunzia including their patented nutraceutical for stress and anxiety and soon FDA approved drug for ASD (Autistic Spectrum of Disorders), including Autism, ADD, ADHD, Fragile X, and PTSD. The Nunzia Nutraceutical aids in Nutritional deficiencies and therefore helps people
“We believe this announcement couldn’t come at a better time for us as we are partnering with Nunzia Pharmaceutical and their products for Neurological disorders,” said Mr. Strongo. “Nunzia Pharmaceutical with a nutraceutical for anxiety and stress based on their patented formulas and there pharmaceutical drug there are planning on bringing through the FDA, which specifically works on the Hippocampus part of the brain, dealing with stress, memory, and fine motor skills are a perfect fit for Global’s diagnostic tests.”
Followers
|
23
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1129
|
Created
|
11/03/15
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |